The estimated Net Worth of Daniel Patrick O'day is at least 69.6 百万$ dollars as of 10 September 2024. Mr. day owns over 10,295 units of Gilead Sciences stock worth over 40,530,219$ and over the last 6 years he sold GILD stock worth over 0$. In addition, he makes 29,107,900$ as Chairman of the Board、 Chief Executive Officer at Gilead Sciences.
Sign up
Mr. Day GILD stock SEC Form 4 insiders trading
Daniel has made over 16 trades of the Gilead Sciences stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 10,295 units of GILD stock worth 833,277$ on 10 September 2024.
The largest trade he's ever made was exercising 54,288 units of Gilead Sciences stock on 1 March 2020 worth over 4,394,071$. On average, Daniel trades about 13,991 units every 72 days since 2019. As of 10 September 2024 he still owns at least 500,744 units of Gilead Sciences stock.
You can see the complete history of Mr. day stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Daniel O'Day biography
Daniel O'Day is appointed as Chairman of the Board, Chief Executive Officer of the company. Mr. O’Day joined Gilead as Chairman and Chief Executive Officer on March 1, 2019. Prior to Gilead, Mr. O’Day served as the Chief Executive Officer of Roche Pharmaceuticals. His career at Roche spanned more than three decades, during which he held a number of executive positions in the company’s pharmaceutical and diagnostics divisions in North America, Europe and Asia. During his time at Roche, Mr. O’Day demonstrated vision and leadership, helping to engineer the acquisitions of Flatiron Health and Foundation Medicine in 2018. He served as a member of Roche’s Corporate Executive Committee, as well as on a number of public and private boards, including Genentech, Inc., Foundation Medicine, Inc. and Chugai Pharmaceutical Co., Ltd. Mr. O’Day holds a bachelor’s degree in biology from Georgetown University and an MBA from Columbia University in New York.
What is the salary of Daniel Day?
As the Chairman of the Board、 Chief Executive Officer of Gilead Sciences, the total compensation of Daniel Day at Gilead Sciences is 29,107,900$. There are no executives at Gilead Sciences getting paid more.
How old is Daniel Day?
Daniel Day is 55, he's been the Chairman of the Board、 Chief Executive Officer of Gilead Sciences since 2019. There are 15 older and 10 younger executives at Gilead Sciences. The oldest executive at Gilead Sciences, Inc. is Richard Whitley, 74, who is the Independent Director.
What's Daniel Day's mailing address?
Daniel's mailing address filed with the SEC is 333 LAKESIDE DRIVE, , FOSTER CITY, CA, 94404.
Insiders trading at Gilead Sciences
Over the last 22 years, insiders at Gilead Sciences have traded over 221,090,692$ worth of Gilead Sciences stock and bought 30,121 units worth 1,879,767$ . The most active insiders traders include John C Martin、Norbert W Bischofberger、John F Milligan. On average, Gilead Sciences executives and independent directors trade stock every 9 days with the average trade being worth of 3,341,365$. The most recent stock trade was executed by Deborah H Telman on 10 September 2024, trading 639 units of GILD stock currently worth 51,721$.
What does Gilead Sciences do?
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
What does Gilead Sciences's logo look like?
Complete history of Mr. day stock trades at Gilead Sciences
Gilead Sciences executives and stock owners
Gilead Sciences executives and other stock owners filed with the SEC include:
-
Daniel O'Day,
Chairman of the Board, Chief Executive Officer -
Johanna Mercier,
Chief Commercial Officer -
Daniel P. O'Day,
Chairman & CEO -
Andrew Dickinson,
Chief Financial Officer, Executive Vice President -
Brett Pletcher,
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary -
Johanna Mercier,
Chief Commercial Officer -
Dr. Merdad V. Parsey M.D., Ph.D.,
Chief Medical Officer -
Merdad Parsey,
Chief Medical Officer -
Brett A. Pletcher,
Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. -
Andrew D. Dickinson,
Exec. VP & CFO -
Per Wold-Olsen,
Independent Director -
Richard Whitley,
Independent Director -
Kelly Kramer,
Independent Director -
Kevin Lofton,
Lead Independent Director -
Harish Manwani,
Independent Director -
Jacqueline Barton,
Independent Director -
Sandra Horning,
Independent Director -
Anthony Welters,
Director -
Javier Rodriguez,
Director -
Michael Quigley,
Senior Vice President - Research Biology -
Linda Higgins,
Senior Vice President - Head of External Innovation -
Jyoti Mehra,
Executive Vice President of Human Resources -
Dr. Linda Slanec Higgins Ph.D.,
Sr. VP & Head of External Innovation -
Jyoti K. Mehra,
Exec. VP of HR -
Deborah H. Telman,
Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. -
Dr. Diana M. Brainard M.D.,
Sr. VP of HIV & Emerging Viral Infections -
Dr. Taiyin Yang,
Exec. VP of Pharmaceutical Devel. & Manufacturing -
Jacquie Ross C.F.A.,
VP of Investor Relations -
Diane E. Wilfong,
Sr. VP, Corp. Controller & Chief Accounting Officer -
John Francis Cogan,
Director -
John W Madigan,
Director -
Robin L Washington,
SVP, CFO -
Norbert W Bischofberger,
SVP, Research -
James R Meyers,
SVP Comm Ops North America -
Nicholas G Moore,
Director -
Gayle E Wilson,
Director -
Kevin Young,
EVP, Commercial Operations -
Laura Hamill,
EVP, Worldwide Commercial Ops -
Carla A Hills,
Director -
Etienne Davignon,
Director -
Paul Rutherford Carter,
EVP Commercial Ops -
John C Martin,
President and CEO -
John F Milligan,
EVP, Chief Financial Officer -
John G Mc Hutchison,
Chief Scientific Off/HeadR&D -
James M Denny,
Director -
Gordon Earle Moore,
Director -
Kristen Metza,
SVP, Human Resources -
Gregg H Alton,
SVP, General Counsel -
Paul Berg,
Director -
Louis G Lange,
EVP Cardiovascular Therapeutic -
Taiyin Yang,
SVP, Pharm Dev & Mfg -
William A Lee,
SVP Research and PPD -
Anthony Caracciolo,
SVP -
Caroline Dorsa,
SVP, Chief Financial Officer -
John J Toole,
SVP -
George P Shultz,
Director -
Alan Bruce Montgomery,
SVP, Respiratory Therapeutics -
Michael K Inouye,
SVP -
Mark L Perry,
EVP Operations -
Cordell W Hull,
Director -
Diane E. Wilfong,
SVP, Controller & CAO -
Sandra Patterson,
SVP, Controllership -
Jeffrey Bluestone,
Director -
Deborah H Telman,
EVP, Corporate Affairs & GC -
Ted W Love,
Director